Combined PD-1 and CCR5 Inhibition for the Treatment of Refractory Microsatellite Stable mCRC (PICCASSO)
A Phase I Trial of Combined PD-1 Inhibition (Pembrolizumab) and CCR5 Inhibition (Maraviroc) for the Treatment of Refractory Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC)
Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
A PHASE1 clinical study on MSS and Metastatic Colorectal Cancer, this trial is completed. The trial is conducted by Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest and has accumulated 14 data snapshots since 2018. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
14 versions recorded-
Feb 2025 — Present [monthly]
Completed PHASE1
-
Sep 2024 — Feb 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE1
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE1
▶ Show 9 earlier versions
-
Jul 2022 — Dec 2022 [monthly]
Completed PHASE1
-
May 2021 — Jul 2022 [monthly]
Completed PHASE1
-
Jan 2021 — May 2021 [monthly]
Completed PHASE1
-
Apr 2020 — Jan 2021 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Jan 2019 — Apr 2020 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Nov 2018 — Jan 2019 [monthly]
Recruiting PHASE1
-
Jun 2018 — Nov 2018 [monthly]
Recruiting PHASE1
-
May 2018 — Jun 2018 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Oct 2017 — May 2018 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
- University Hospital Heidelberg
For direct contact, visit the study record on ClinicalTrials.gov .